Fourth Edition

Unmet Needs

New Drugs

Of three new therapies on the horizon in the last edition, abaloparatide (brand name Tymlos) and romosozumab (brand name Evenity) have been approved by the FDA for the treatment of osteoporosis.

Unmet Needs

  • Educating military providers on medical coding within the military system to ensure accurate data for continued analysis to direct future research and funding.
  • Identifying those at risk for stress fractures, particularly in boot camp, and continuing investigation on prevention strategies and nutritional supplementation.  
  • Additional research on efficacy of pre-training protocols in preventing acute musculoskeletal injuries such as fractures, ligament ruptures, and joint dislocations in the active duty military population.

Key Challenges to the Future

The impact of musculoskeletal injuries on the service member does not stop when they leave the military. Degenerative conditions have been shown to plague the aging military population. Fragility fractures are less common in the active duty population, but certainly have a profound effect on the Veteran community. The years of consistent physical demands placed on the bodies of Active Duty service members results in life-long musculoskeletal issues, particularly post-traumatic arthritis, as well as psychological disturbances from chronic pain.

Pages

Subscribe to Fourth Edition